GE HealthCare Technologies Inc. (GEHC) Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics:

Q4 Revenue: $5.7 billion, up 4.8% organically year-over-year.

Product Revenue: Grew 7.9%; Service Revenue: Grew 5.5%.

Orders Growth: 2% in Q4, with a record backlog of $21.8 billion, up $2 billion year-over-year.

Adjusted EBIT Margin: 16.7%, down 200 basis points due to $100 million in tariff expenses.

Adjusted EPS: $1.44, down 0.7% (11% growth excluding tariff impact).

Free Cash Flow: $916 million, up $105 million year-over-year.

2Strategic Updates and Business Highlights:

Innovation Focus: Continued emphasis on new product launches, with 55% of revenue from new products.

Acquisitions: Planned acquisition of IntelliRed expected to enhance cloud-first imaging ecosystem, projected revenues of $270 million in the first year.

Heartbeat System: Implementation of Heartbeat business system aimed at improving operational efficiency and customer experience.

Enterprise Agreements: Secured multiple large agreements, including a notable seven-year deal with the University of Rochester Medical Center.

3Forward Guidance and Outlook:

2026 Revenue Growth: Expected organic growth of 3% to 4%.

Adjusted EBIT Margin: Projected between 15.8% to 16.1%.

Adjusted EPS Guidance: Anticipated range of $4.95 to $5.15, representing 8% to 12% growth.

Free Cash Flow: Expected to reach approximately $1.7 billion, a 13% increase.

4Bad News, Challenges, or Points of Concern:

Tariff Impact: Continued tariff expenses are expected to affect margins, though less than in 2025.

China Market: Anticipated decline in China, with cautious outlook due to previous growth challenges and ongoing tender disputes.

Order Growth: Q4 order growth was lower than the previous year, raising concerns about future demand.

Margin Pressure: Adjusted EBIT margin declined year-over-year, indicating ongoing cost pressures.

5Notable Q&A Insights:

Order Growth Composition: Management expressed optimism about the order book despite a modest growth rate, citing strong backlog and upcoming product approvals as positive indicators for 2026.

Florcato Supply: Positive feedback on Florcato's adoption, with plans to increase weekly doses as supply stabilizes.

China's Performance: Management remains cautious about the Chinese market, expecting declines but noting improvements in commercial execution.

Service Revenue Growth: Service revenue grew 6% in 2025, with expectations for continued robust growth driven by new product introductions and increased utilization. Overall, GEHC demonstrated strong financial performance in Q4 2025, with a focus on innovation and strategic growth initiatives, while navigating challenges related to tariffs and market conditions in China. The outlook for 2026 remains cautiously optimistic, supported by a solid backlog and new product launches.